Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. F Gennaro
Prof. Salvatore Novo,
Carotid IMT has been shown to be an independent marker of multifocal atherosclerosis. Now it is established that IMT is an independent predictor for cerebro- and cardiovascular events : an increase in the thickness of the intima and media of the carotid artery -as measured non-invasively by ultrasonography- is directly associated with an increased risk of myocardial infarction and stroke in adults without a history of cardiovascular disease.
Cardiovascular diseases remain today the first cause of death in the world. Understandably, the knowledge and the prevention of cardiovascular risk factors have attracted particular attention. Beyond “traditional” risk factors such as age, gender, family history of CV disease, hypertension, hyperlipidemia, smoking and diabetes, very important as well, are “emerging” risk factors such as fibrinogen, metabolic syndrome (MS), hsCRP, Lp-(a), hyperhomocysteinemia and instrumental markers such as Ankle Brachial Index (ABI) and carotid Intima-Media Thickness (IMT).
Particularly, IMT is a non invasive low cost and highly reproducible procedure.
Carotid Artery IMT is measured with laser Doppler velocimetry: the ultrasonographic assessment of carotid arteries is operated while the subject is in a supine position with his head turned to the sonographer at an angle of 45°.
The scan head is kept perpendicular to the arterial walls. The Doppler mode permits the visualisation of vessels and an evaluation of flow disturbances. It measures the intima-media thickness (IMT) and the size and number of atheromatous plaques. IMT is defined as the distance between the media-adventitia interface and the intima-media interface.
IMT is measured at five locations on each side and, in particular, it is measured at internal carotid artery (ICA) about 1 cm distal from the flow divider, at bifurcation enlargement (BIF) and at proximal, middle and distal segment of the common carotid artery (CCA) is measured.
Cardiovascular RF are associated with an impaired endothelial function and an increased IMT, and the presence of carotid IMT is significantly related with endothelial dysfunction (p < 0.01). In a study of our group impaired flow mediated vasodilatation (FMD) and values of carotid IMT have been found to be higher among patients with cardiovascular risk factors than among patients without RF. Age (p < 0.005) and diabetes (p < 0.05) and levels oh hsCRP were directly related to carotid IMT. An inverse linear correlation was shown between systolic blood pressure (p < 0.005), smoking (p < 0.05), total cholesterol (p < 0.05), LDL-C plasma levels (p < 0.005), hsCRP levels and FMD. Finally, we showed a lower FMD in patients with carotid and femoral IMT in comparison with patients without peripheral atherosclerosis (p = 0.01) (1).
Another study showed the major prevalence of endothelial dysfunction in hypertensive patients and in normotensive offspring of subjects with essential hypertension, proving the importance of genetic predisposition (2).
Clinical studies have shown an important relation between smoking and IMT: non smokers had lower IMT values than smokers (p < 0.01) and smoking was associated with dose-related increases in intima-media thickness and endothelial dysfunction (3).
Furthermore, there is an interrelationship between total risk and IMT: IMT depends on the presence and a number of risk factors, duration and their intensity. In fact IMT increases with age and hypertension, hyperlipidemia and non-insulin-dependent diabetes mellitus are related to a higher IMT (4).
A relation between IMT and the cluster of risk factors of the Metabolic Syndrome has also been shown: in fact, a number of MS components and IMT value increases proportionately and in patients with manifest vascular disease, the presence of metabolic syndrome is associated with advanced vascular damage (5).
Another study examined the relation between IMT and a number of arterial beds with significant (> 50%) stenoses, including coronary, supra-aortic, renal and iliac/femoral arteries. It showed that IMT was significantly correlated to the number of coronary vessels with stenoses (p<0.001). So, IMT has been shown to be an independent predictor of significant multifocal atherosclerosis, showing high sensitivity and specificity for indicating more advanced atherosclerotic involvement (6, 7).
Previous observational studies have shown a relationship between carotid intima-media thickness (IMT) and coronary artery disease (CAD). Many studies such as the “Prospective Finnish Study”, “Atherosclerotic Risk in Communities (ARIC)”, the “Rotterdam Study” and the “Cardiovascular Health Study” showed a significant relation between IMT and cardiovascular risk and provided evidence that carotid IMT is related to future cerebrovascular and cardiovascular events (8-12). The ACSRS study determined the risk of ipsilateral ischaemic neurological events in relation to the degree of asymptomatic carotid stenosis and other risk factors. It showed linearity between stenosis and risk, and provided a new approach to risk stratification (13). In a study of our group, performed in asymptomatic high risk subjects followed for 5 years, a significant increase of fatal and non fatal cerebro- and cardiovascular events in those subjects that at baseline present IMT or asymptomatic carotid plaques in comparison to subjects with normal carotid arteries at baseline was shown (14).
Moreover, in this study, beyond traditional cardiovascular risk factors, markers of inflammation and previous infections to Cytomegalovirus, Chlamydia pneumoniae, Helicobacter pylori e Cytotoxic Helicobacter pylori seem to significantly influence the occurrence of cerebrovascular and cardiovascular events in patients with baseline asymptomatic carotid lesions (p<0.0001) (14).
In the Multiple Risk Factor Intervention Trial (MRFIT) it has been demonstrated that multiple risk factor intervention reduces cardiovascular risk in high-risk hypertensive men, and that this effect is confined to patients with carotid artery plaques and, in particular, to those patients with echolucent plaques (15). The Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP study) studied the long-term effects of statins on femoral IMT. It demonstred an increased efficacy of atorvastatin 80 mg in delaying the progression of atherosclerosis in the femoral artery (16). Some antihypertensive agents influence experimental models of atherosclerosis through mechanisms independent of blood pressure lowering, as shown in the European Lacidipine Study on Atherosclerosis (ELSA), a randomised, double-blind, long-term trial, comparing the effects of a 4-year treatment based on either lacidipine or atenolol on an index of carotid atherosclerosis. The antihypertensive treatment with lacidipine slowed down progression of carotid atherosclerosis significantly more than atenolol treatment. Clinic blood pressure reductions were identical with both treatments, even if 24-hour ambulatory systolic/diastolic blood pressure decreased more with atenolol (-10/-9 mm Hg) than with lacidipine (-7/-5 mm Hg). However, the ELSA study showed the greater efficacy of lacidipine on carotid IMT progression. These results, despite a smaller ambulatory blood pressure reduction, indicated an anti-atherosclerotic action of lacidipine independent of its antihypertensive action (17). Data from our study (14) and other data from a recent paper on the evaluation of patients with apparently moderate risk using the Framingham score (18), demonstrate that patients with a cluster of risk factors and IMT have a cardiovascular risk at ten years > 20%; consequently these patients should have applied the concept that “lower cholesterol is better” and be treated with statins to reach a target of LDL-C < 100 mg%.
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.
1. Corrado E, Muratori I, Tantillo R, Contorno F, Coppola G, Strano A, Novo S. Relationship between endothelial dysfunction, intima media thickness and cardiovascular risk factors in asymptomatic subjects. Int Angiol 2005; 24: 52-8 2. Žižek B., Poredoš P. Endothelial dysfunction in hypertensive patients and in normotensive offspring of subjects with essential hypertension. Heart 2001; 85: 215-7 3. Poredoš P et al., Smoking is associated with dose-related increase of intima-media thickness and endothelial dysfunction. Angiology 1999; 50: 201-8 4. Novo S, Pernice C, Barbagallo C M, Tantillo R, Caruso R, Longo B. Influence of risk factors and aging on asymptomatic carotid lesions. In: Advances in Vascular Pathology 1997, A. N. Nicolaides and S. Novo (Eds.), Elsevier Science, Excerpta Medica, Amsterdam, 1997, pp. 33-44 5. Olijhoek et al., The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. Euro Heart J 2004; 25: 342-8 6. Kablak-Ziembicka A. Relationship between carotid intima-media thickness, atherosclerosis risk factors and angiography findings in patients with coronary artery disease. Acta Cardiol.2002; 57:40-1. 7. Balbarini A et al., Usefulness of carotid intima-media thickness measurement and peripheral B-mode ultrasound scan in the clinical screening of patients with coronary artery disease. Angiology 2000; 51: 269-79 8. Salonen JT, Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. Arterioscl Thromb 1991; 11: 1245-1249 9. Burke GL, Role of social class in excess black stroke mortality. Stroke 1995; 26: 386-91 10. Chambless LE, Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 2000; 151: 478-87 11. Bots ML. Tissue plasminogen activator and risk of myocardial infarction. The Rotterdam Study. Circulation 1997; 96: 1432-1437 12. O'Leary DH. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. NEJM 1999; 340: 14-22 13. Nicolaides A. N. et al. Severity of asymptomatic carotid stenosis and risk of ipsilateral hemispheric ischaemic events: results from the ACSRS study. Eur J Vasc Endovasc Surg 2005; 30: 275-284 14. Corrado E, Rizzo M, Tantillo R, Muratori I, Bonura F, Vitale G, Novo S. Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions: a 5-year follow-up study. Stroke 2006; 37:482-6 15. Schmidt C et al, Multiple risk factor intervention reduces cardiovascular risk in hypertensive patients with echolucent plaques in the carotid artery. J Intern Med 2003; 253: 430-8 16. Van Wissen S, Smilde TJ, de Groot E, Hutten BA, Kastelein JJ, Stalenhoef AF, The significance of femoral intima-media thickness and plaque scoring in the Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) study. Eur J Cardiovasc Prev Rehabil 2003;10: 451-5 17. Zanchetti A et al, Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106: 2422-7 18. Abe Y, Rundek T, Sciacca RR, Jin Z, Sacco RL, Homma S, Di Tullio MR. Ultrasound assessment of subclinical cardiovascular disease in a community-based multiethnic population and comparison to the Framingham Score, Am J Cardiology 2006; 98:1374-8
*Chair of Cardiovascular Diseases, post-graduate School of Cardiology, Master of Vascular Diseases & Division of Cardiology, University Hospital “P. Giaccone” of the of University of Palermo, Italy. *Prof. S. Novo , Prof. F. Gennaro, Palermo, Italy *Past-chairman of the Working Group on Peripheral Circulation
© 2017 European Society of Cardiology. All rights reserved